Three, moving to digital PCR. Our teams expanded the capabilities of the QIAcuity system with the launch of our QIAcuity Diagnostic for clinical use. Here, we are focusing on oncology and ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced financial results for the fourth quarter and ...

Net sales of $525 million CER ahead of outlook for at least $520 million CER and adjusted diluted EPS of $0.61 CER ahead of outlook for at least $0.60 CER QIAstat-Dx, QuantiFERON and QIAcuity ...

Reports Q4 revenue $521M, consensus $518.54M. The company said, “Our solid sales growth in the second half of 2024 mirrors our plans for ...

Bernard emphasized strong performances in the QIAstat Diagnostics and QuantiFERON portfolios, with QIAstat achieving 25% CER growth in Q4 and over 660 new system placements in 2024. QuantiFERON grew ...

QIAcuity also delivered solid growth despite challenging instrument purchase trends as we expanded digital PCR into clinical use in 2024 while expanding our presence with academia, pharma and other ...

The company made significant strides in the QIAcuity digital PCR system, including the addition of 100 new validated assays in areas such as cancer research, inherited genetic disorders and ...

QIAGEN N.V.’s QGEN fourth-quarter 2024 adjusted earnings per share (EPS) were 61 cents, the same at the constant exchange ...

QIAGEN N.V.’s QGEN long-term business strategy focuses on forming partnerships for the development, commercialization, marketing and distribution of existing and future products. The company sees ...